Clinical Trial Update: Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of SPH4336, a CDK4/6 inhibitor, in locally advanced or metastatic liposarcoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liposarcoma Dedifferentiated

Drugs mentioned

• SPH4336

Snippet

Sponsor: Shanghai Pharma Biotherapeutics USA Inc. | Conditions: Liposarcoma, Dedifferentiated | Phase 2 | Status: TERMINATED | Results posted: 2025-06-13